Quick Links

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Astex Pharmaceuticals, Inc, and Celgene Corporation.

Medical Crossfire®: Changing the Paradigm in Myelodysplastic Syndromes: How Do Patient Factors Impact Treatment Decisions?

Release Date: December 31, 2018
Expiration Date: December 31, 2019
Media: Internet - based

Activity Overview

This activity, Medical Crossfire®: Changing the Paradigm in Myelodysplastic Syndromes: How Do Patient Factors Impact Treatment Decisions? is designed to update clinicians on the latest strategies to optimize outcomes for patients with myelodysplastic syndromes (MDS). As clinicians who treat patients with MDS, you require a solid understanding of the diagnostic criteria used to accurately identify patients with MDS, and to rule out other potential hematologic disorders. In addition, you need to be aware of revisions to the revised International Prognostic Scoring System (IPSS-R) for MDS, how these changes impact risk categorization, and implications for treatment selection. It is vital to understand when to observe and when to treat a patient newly diagnosed with MDS, and how to select between the available therapeutic options. For patients with relapsed or refractory MDS, it is essential to be aware of current options and how to individualize treatment plans. Finally, you want to be up-to-date on emerging agents and clinical trial options to expand opportunities for your patients with MDS.

To help you meet these goals, we have developed an educational activity that features case-based interactive discussions with our panel of experts, who will share their perspectives on diagnosing MDS and assessing risk, as well as state-of-the-art treatment strategies and the latest clinical trial data so that you can appropriately optimize the care and management of your patients.

Benefits of Participating

  • Understand how to diagnose and categorize MDS
  • Learn how to tailor available treatment options for patients with MDS based on risk classification and patient comorbidities
  • Hear experts discuss how they apply guidelines and data to real-world patient scenarios
  • Explore options for clinical trials investigating novel agents and new strategies for MDS

Acknowledgement of Commercial Support

This activity is supported by educational grants from Astex Pharmaceuticals, Inc, and Celgene Corporation.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward hematologists, oncologists, fellows, nurse practitioners, physician assistants, nurses, and other healthcare professionals interested in the treatment of MDS.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Explain the current categorization of MDS disease and how risk stratification informs clinical decision-making
  • Describe current treatment strategies for MDS and guidelines, and how risk for progression to acute myeloid leukemia (AML) impacts management
  • Determine how individual patient characteristics impact prognosis, including response to therapies, survival, or progression to AML
  • Place recent evidence concerning novel MDS treatment strategies into the context of evolving treatment paradigms in the field

Faculty, Staff, and Planners' Disclosures


David P. Steensma, MD
Associate Professor of Medicine
Harvard Medical School
Institute Physician
Adult Leukemia Program
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Grant/Research Support: Celgene, H3 Biosciences; Consultant: Novartis, Janssen, Otsuka, Takeda, Sensei; Stock/Shareholder: Array, Galectin


Jamie Koprivnikar, MD
Medical Oncologist
John Theurer Cancer Center
Hackensack, NJ

Disclosures: Consultant: Partner Therapeutics, Alexion; Speakers Bureau: Alexion, Amgen

Aziz Nazha, MD
Assistant Professor
Lerner College of Medicine
Associate Staff
Taussig Cancer Institute
Cleveland Clinic
Cleveland, OH

Disclosures: Consultant: Karyopharm, Tolero; Data Monitoring Committee: MEI

Amer Zeidan, MDDS, MHS
Assistant Professor of Medicine
Yale University School of Medicine
Yale Cancer Center
New Haven, CT

Disclosures: Grant/Research Support: Celgene, Acceleron, Pfizer; Consultant: Celgene, Pfizer, Acceleron, Astellas, Daiichi Sankyo, Otsuka, AbbVie, Ariad, Novartis, Takeda, Agios; Speakers Bureau: Takeda

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Become a Member

Forgot Password?
Calendar of Events
Filter By